{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:39:40Z","timestamp":1790746780882,"version":"4.1.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Incyte Corporation"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.clml.2014.11.002","type":"journal-article","created":{"date-parts":[[2014,11,18]],"date-time":"2014-11-18T05:56:52Z","timestamp":1416290212000},"page":"253-261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Impact of Bone Marrow Pathology on the Clinical Management of Philadelphia Chromosome\u2013Negative Myeloproliferative Neoplasms"],"prefix":"10.1016","volume":"15","author":[{"given":"Olga","family":"Pozdnyakova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Hasserjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Orazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2014.11.002_bib1","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.11.002_bib2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.11.002_bib3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/asheducation-2011.1.208","article-title":"Genetic and epigenetic complexity in myeloproliferative neoplasms","volume":"2011","author":"Cross","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2014.11.002_bib4","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.11.002_bib5","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.11.002_bib6","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.11.002_bib7","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of\u00a0somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.11.002_bib8","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A\u00a0prospective study of 338 patients with\u00a0polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on\u00a0fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.11.002_bib9","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.11.002_bib10","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1182\/blood-2013-02-486050","article-title":"Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms","volume":"121","author":"Rumi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.11.002_bib11","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations\u2013based molecular prognostication in primary myelofibrosis: an international study of 570\u00a0patients","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.11.002_bib12","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3324\/haematol.2014.107482","article-title":"Distinct clinical characteristics in myeloproliferative neoplasms with calreticulin mutations","volume":"99","author":"Andrikovics","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.11.002_bib13","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.11.002_bib14","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.11.002_bib15","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/leu.2011.253","article-title":"IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F","volume":"26","author":"Tefferi","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.11.002_bib16","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/modpathol.2013.109","article-title":"Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage","volume":"26","author":"Boiocchi","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clml.2014.11.002_bib17","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/ajh.22166","article-title":"Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm","volume":"86","author":"Rumi","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2014.11.002_bib18","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2009-08-240135","article-title":"International Prognostic Scoring System\u2014independent cytogenetic risk categorization in primary myelofibrosis","volume":"115","author":"Hussein","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.11.002_bib19","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.11.002_bib20","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.11.002_bib21","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A\u00a0dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.11.002_bib22","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/leu.2011.374","article-title":"Leukemia risk models in primary myelofibrosis: an International Working Group study","volume":"26","author":"Tefferi","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.11.002_bib23","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.11.002_bib24","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","article-title":"A\u00a0prognostic model to predict survival in 867 World Health Organization\u2013defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment","volume":"120","author":"Passamonti","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.11.002_bib25","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.11.002_bib26","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1182\/blood-2010-11-315614","article-title":"How I treat myelofibrosis","volume":"117","author":"Tefferi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.11.002_bib27","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post\u2013polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.11.002_bib28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11899-013-0186-x","article-title":"WHO classification of myeloproliferative neoplasms (MPN): a\u00a0critical update","volume":"8","author":"Kvasnicka","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2014.11.002_bib29","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1182\/blood-2010-07-293761","article-title":"Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification","volume":"117","author":"Thiele","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.11.002_bib30","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/leu.2013.99","article-title":"Personalized management of essential thrombocythemia\u2014application of recent evidence to clinical practice","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.11.002_bib31","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ajh.23617","article-title":"Masked polycythemia vera diagnosed according to WHO and BCSH classification","volume":"89","author":"Barbui","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2014.11.002_bib32","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood-2013-06-508416","article-title":"Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis","volume":"122","author":"Silver","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.11.002_bib33","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ajh.23694","article-title":"Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients","volume":"89","author":"Barbui","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2014.11.002_bib34","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/ajh.23585","article-title":"Masked polycythemia vera (mPV): results of an international study","volume":"89","author":"Barbui","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2014.11.002_bib35","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.cancergen.2013.02.002","article-title":"Myelofibrosis in Philadelphia chromosome\u2013negative myeloproliferative neoplasms is associated with aberrant karyotypes","volume":"206","author":"Hauck","year":"2013","journal-title":"Cancer Genet"},{"key":"10.1016\/j.clml.2014.11.002_bib36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cytogfr.2013.01.004","article-title":"The role of cytokines in the initiation and progression of myelofibrosis","volume":"24","author":"Hasselbalch","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"issue":"suppl 1","key":"10.1016\/j.clml.2014.11.002_bib37","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1186\/1755-1536-5-S1-S20","article-title":"Primary myelofibrosis and the \u201cbad seeds in bad soil\u201d concept","volume":"5","author":"Le Bousse-Kerdil\u00e8s","year":"2012","journal-title":"Fibrogenesis Tissue Repair"},{"key":"10.1016\/j.clml.2014.11.002_bib38","first-page":"69","article-title":"Cellular and molecular mechanisms underlying bone marrow and liver fibrosis: a review","volume":"19","author":"Le Bousse-Kerdil\u00e8s","year":"2008","journal-title":"Eur Cytokine Netw"},{"issue":"suppl 1","key":"10.1016\/j.clml.2014.11.002_bib39","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1186\/1755-1536-5-S1-S21","article-title":"Myelofibrosis: molecular and cell biological aspects","volume":"5","author":"Kreipe","year":"2012","journal-title":"Fibrogenesis Tissue Repair"},{"key":"10.1016\/j.clml.2014.11.002_bib40","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood-2008-06-158386","article-title":"Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence","volume":"112","author":"Lataillade","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.11.002_bib41","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.leukres.2011.01.013","article-title":"Bone marrow fibrosis in myeloproliferative neoplasms-associated myelofibrosis: deconstructing a myth?","volume":"35","author":"Barosi","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2014.11.002_bib42","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/978-1-61779-163-5_34","article-title":"Laser-capture microdissection and analysis of liver endothelial cells from patients with Budd-Chiari syndrome","volume":"755","author":"Sozer","year":"2011","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.clml.2014.11.002_bib43","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/blood-2012-02-402594","article-title":"Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection","volume":"120","author":"Papadantonakis","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.11.002_bib44","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1080\/1042819031000077070","article-title":"Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients","volume":"44","author":"Thiele","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.11.002_bib45","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.11.002_bib46","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1038\/modpathol.2014.69","article-title":"High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms","volume":"27","author":"Pozdnyakova","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clml.2014.11.002_bib47","unstructured":"Kvasnicka HM, Thiele J, Orazi A, et\u00a0al. Criteria for therapy response and progression in patients with myelofibrosis based on bone marrow features [abstract 1410]. Paper presented at: 103rd USCAP Annual Meeting; March 1-7, 2014; San\u00a0Diego, Calif."},{"key":"10.1016\/j.clml.2014.11.002_bib48","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/modpathol.2012.87","article-title":"The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis","volume":"25","author":"Gianelli","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clml.2014.11.002_bib49","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s12032-014-0869-8","article-title":"Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis","volume":"31","author":"Lekovic","year":"2014","journal-title":"Med Oncol"},{"key":"10.1016\/j.clml.2014.11.002_bib50","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.3109\/10428194.2013.769537","article-title":"Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis","volume":"54","author":"Nazha","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.11.002_bib51","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.2008.20.3174","article-title":"Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy","volume":"27","author":"Campbell","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.11.002_bib52","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-11-393819","article-title":"Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome","volume":"119","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2014.11.002_bib53","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1186\/1755-1536-5-S1-S25","article-title":"Replacement of hematopoietic system by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosis","volume":"5","author":"Kr\u00f6ger","year":"2012","journal-title":"Fibrogenesis Tissue Repair"},{"key":"10.1016\/j.clml.2014.11.002_bib54","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.exphem.2007.08.022","article-title":"Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis","volume":"35","author":"Kr\u00f6ger","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1016\/j.clml.2014.11.002_bib55","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.bbmt.2014.02.019","article-title":"Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis","volume":"20","author":"Kr\u00f6ger","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2014.11.002_bib56","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/BF02685904","article-title":"Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment","volume":"24","author":"Hultdin","year":"2007","journal-title":"Med Oncol"},{"key":"10.1016\/j.clml.2014.11.002_bib57","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1179\/102453309X12473408860587","article-title":"Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission","volume":"14","author":"Stauffer Larsen","year":"2009","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2014.11.002_bib58","first-page":"1124","article-title":"Reversal of bone marrow fibrosis in idiopathic myelofibrosis after treatment with alpha-interferon","volume":"83","author":"Domingues","year":"1998","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.11.002_bib59","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/leu.2009.90","article-title":"Recombinant interferon alpha (rIFN\u03b1-2b) may retard progression of early primary myelofibrosis","volume":"23","author":"Silver","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.11.002_bib60","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1182\/blood-2010-11-320069","article-title":"Recombinant interferon-\u03b1 may retard progression of early primary myelofibrosis: a preliminary report","volume":"117","author":"Silver","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.11.002_bib61","unstructured":"Zhou J, Gong P, Silver RT, et\u00a0al. Recombinant interferon alpha therapy decreases bone marrow fibrosis and cellularity and improves megakaryocyte morphology in a significant portion of patients with myelofibrosis [abstract 1597]. Paper presented at: 103rd USCAP Annual Meeting; March 1-7, 2014; San Diego, Calif."},{"key":"10.1016\/j.clml.2014.11.002_bib62","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.3324\/haematol.10684","article-title":"Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly","volume":"92","author":"Berrebi","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.11.002_bib63","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1200\/JCO.2009.22.6548","article-title":"Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.11.002_bib64","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A\u00a0double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.11.002_bib65","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.11.002_bib66","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/bjh.12274","article-title":"The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis","volume":"161","author":"Verstovsek","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.11.002_bib67","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1182\/blood.V122.21.396.396","article-title":"Long-term outcomes of ruxolitinib therapy in patients with myelofibrosis: 3-year update from COMFORT-I [abstract]","volume":"122","author":"Verstovsek","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.11.002_bib68","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3324\/haematol.2013.092155","article-title":"Efficacy, safety and survival with ruxolitinib\u00a0in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I","volume":"98","author":"Verstovsek","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.11.002_bib69","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.11.002_bib70","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood-2013-12-544411","article-title":"Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts","volume":"123","author":"Passamonti","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.11.002_bib71","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.3324\/haematol.2013.095109","article-title":"Resolution of bone marrow fibrosis in a patient receiving JAK1\/JAK2 inhibitor treatment with ruxolitinib","volume":"98","author":"Wilkins","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.11.002_bib72","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s00277-014-2096-y","article-title":"Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve?","volume":"93","author":"Molica","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2014.11.002_bib73","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a\u00a0JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl","key":"10.1016\/j.clml.2014.11.002_bib74","article-title":"Exploratory analysis of the effect of ruxolitinib on bone marrow morphology in patients with myelofibrosis [abstract 7030]","volume":"31","author":"Kvasnicka","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.11.002_bib75","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood.V122.21.4055.4055","article-title":"Effects of five-years of ruxolitinib therapy on bone marrow morphology in patients with myelofibrosis and comparison with best available therapy [abstract]","volume":"122","author":"Kvasnicka","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.11.002_bib76","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1182\/blood.V122.21.4056.4056","article-title":"Effects of ruxolitinib therapy on megakaryocyte morphology and inflammatory bone marrow reaction in patients with myelofibrosis [abstract]","volume":"122","author":"Kvasnicka","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.11.002_bib77","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1182\/blood.V122.21.2823.2823","article-title":"Effect of treatment with the JAK2-selective inhibitor fedratinib (SAR302503) on bone marrow histology in patients with myeloproliferative neoplasms with myelofibrosis [abstract]","volume":"122","author":"Jamieson","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.11.002_bib78","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1182\/blood.V118.21.2814.2814","article-title":"Phase I study of the JAK2 V617F\u00a0inhibitor, LY2784544, in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) [abstract]","volume":"118","author":"Verstovsek","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.11.002_bib79","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/bjh.12220","article-title":"A\u00a0phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera\/essential\u00a0thrombocythaemia myelofibrosis (post-PV\/ET MF)","volume":"161","author":"Mascarenhas","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.11.002_bib80","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1182\/blood.V122.21.662.662","article-title":"Imetelstat, a telomerase inhibitor, induces morphologic and molecular remissions in myelofibrosis and reversal of bone marrow fibrosis [abstract]","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.11.002_bib81","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.ajpath.2012.05.033","article-title":"The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis","volume":"181","author":"Kirabo","year":"2012","journal-title":"Am J Pathol"},{"issue":"suppl","key":"10.1016\/j.clml.2014.11.002_bib82","article-title":"Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrois: stage 1 results [abstract 7114]","volume":"32","author":"Verstovsek","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.11.002_bib83","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2141.1979.tb03740.x","article-title":"The reticulin content of bone marrow in acute leukaemia in adults","volume":"43","author":"Manoharan","year":"1979","journal-title":"Br J Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014004960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014004960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:25:52Z","timestamp":1761870352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265014004960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":83,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S2152265014004960"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2014.11.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Bone Marrow Pathology on the Clinical Management of Philadelphia Chromosome\u2013Negative Myeloproliferative Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2014.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}